Somatic mutations and deletions of the e-cadherin gene predict poor survival of patients with gastric cancer

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 868-875

  Corso, Giovanni ^a,c   Carvalho, Joana ^c   Marrelli, Daniele ^a   Vindigni, Carla ^b   Carvalho, Beatriz ^d   Seruca, Raquel ^c   Roviello, Franco ^a   Oliveira, Carla ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c UNIVERSITY OF PORTO   (Portugal)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; UVOMORULIN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FAMILIAL CANCER; FEMALE; GASTRECTOMY; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; GERM LINE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTICENTER STUDY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SOMATIC MUTATION; STOMACH CANCER; STOMACH SURGERY; SURVIVAL RATE;

ADULT; AGED; CADHERINS; DNA METHYLATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

EID: 84875753760     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.4612     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
2. Dassen AE, Lemmens VE, van de Poll-Franse LV, et al: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands. Eur J Cancer 46:1101-1110, 2010.
3. Brenner H, Francisci S, de Angelis R, et al: Longterm survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 45:1028-1041, 2009.
4. Berrino F, De Angelis R, Sant M, et al: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study. Lancet Oncol 8:773-783, 2007. (Pubitemid 47321600)
5. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006.
6. Schuhmacher C, Gretschel S, Lordick F, et al: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28:5210-5218, 2010.
7. Milne AN, Carneiro F, O'Morain C, et al: Nature meets nurture: Molecular genetics of gastric cancer. Hum Genet 126:615-628, 2009.
8. Nobili S, Bruno L, Landini I, et al: Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 17:290- 299, 2011.
9. Lauren P: The two histological main types of gastric carcinoma: Diffuse and So-called intestinaltype carcinoma-An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49, 1965.
10. Yamashita K, Sakuramoto S, Katada N, et al: Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: The latest comparative study to intestinal advanced gastric cancer. Hepatogastroenterology 56:276-281, 2009.
11. Marrelli D, Roviello F, de Manzoni G, et al: Different patterns of recurrence in gastric cancer depending on Lauren's histological type: Longitudinal study. World J Surg 26:1160-1165, 2002. (Pubitemid 36920276)
12. Oliveira C, Seruca R, Carneiro F: Hereditary gastric cancer. Best Pract Res Clin Gastroenterol 23:147-157, 2009.
13. Fitzgerald RC, Hardwick R, Huntsman D, et al: Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436-444, 2010.
14. Guilford P, Hopkins J, Harraway J, et al: E-cadherin germline mutations in familial gastric cancer. Nature 392:402-405, 1998. (Pubitemid 28168738)
15. Oliveira C, Bordin MC, Grehan N, et al: Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 19:510-517, 2002. (Pubitemid 34461624)
16. Oliveira C, Senz J, Kaurah P, et al: Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 18:1545-1555, 2009.
17. Pinheiro H, Bordeira-Carriço R, Seixas S, et al: Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 19:943-952, 2010.
18. Carneiro F, Huntsman DG, Smyrk TC, et al: Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681-687, 2004. (Pubitemid 38714105)
19. Barber M, Murrell A, Ito Y, et al: Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 216:295-306, 2008.
20. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823, 1971.
21. Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162, 2001. (Pubitemid 33741891)
22. Oliveira C, de Bruin J, Nabais S, et al: Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 23:2236-2240, 2004. (Pubitemid 38482539)
23. Oliveira C, Sousa S, Pinheiro H, et al: Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 136:2137- 2148, 2009.
24. Grady WM, Willis J, Guilford PJ, et al: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26:16-17, 2000.
25. Becker KF, Atkinson MJ, Reich U, et al: E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845-3852, 1994. (Pubitemid 24241205)
26. Berx G, Becker KF, Höfler H, et al: Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12:226-237, 1998. (Pubitemid 28418891)
27. Machado JC, Soares P, Carneiro F, et al: E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 79:459-465, 1999. (Pubitemid 29190435)
28. Carvalho J, van Grieken NC, Pereira PM, et al: Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 upregulation in intestinal gastric cancer. J Pathol 228:31-44, 2012.
29. Machado JC, Oliveira C, Carvalho R, et al: E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20:1525-1528, 2001. (Pubitemid 32291203)
30. Liu YC, Shen CY, Wu HS, et al: Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol 12:2168- 2173, 2006.
31. Ascañao JJ, Frierson H Jr, Moskaluk CA, et al: Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 14:942-949, 2001. (Pubitemid 32976780)
32. Graziano F, Arduini F, Ruzzo A, et al: Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: Implications for treatment with demethylating drugs. Ann Oncol 15:489- 492, 2004. (Pubitemid 38444555)
33. Tamura G, Yin J, Wang S, et al: E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92:569-573, 2000. (Pubitemid 30212319)
34. Graziano F, Arduini F, Ruzzo A, et al: Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, nodepositive, diffuse gastric cancer. Clin Cancer Res 10: 2784-2789, 2004. (Pubitemid 38509156)
35. Biondi A, Persiani R, Cananzi F, et al: R0 resection in the treatment of gastric cancer: Room for improvement. World J Gastroenterol 16:3358- 3370, 2010.
36. Marrelli D, Pedrazzani C, Morgagni P, et al: Changing clinical and pathological features of gastric cancer over time. Br J Surg 98:1273-1283, 2011.
37. Mayer B, Johnson JP, Leitl F, et al: E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53: 1690-1695, 1993. (Pubitemid 23113253)
38. Gamboa-Dominguez A, Dominguez-Fonseca C, Chavarri-Guerra Y, et al: E-cadherin expression in sporadic gastric cancer from Mexico: Exon 8 and 9 deletions are infrequent events associated with poor survival. Hum Pathol 36:29-35, 2005. (Pubitemid 40215631)
39. Han MA, Oh MG, Choi IJ, et al: Association of family history with cancer recurrence and survival in patients with gastric cancer. J Clin Oncol 30:701- 708, 2012.
40. Palli D, Russo A, Saieva C, et al: Dietary and familial determinants of 10-year survival among patients with gastric carcinoma. Cancer 89:1205-1213, 2000.
41. Gao Y, Hu N, Han X, et al: Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer 9:269, 2009.
42. Roviello F, Pedrazzani C, Marrelli D, et al: Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol 36:439-446, 2010.
43. Chiaravalli AM, Klersy C, Vanoli A, et al: Histotype-based prognostic classification of gastric cancer. World J Gastroenterol 18:896-904, 2012.
44. Vandewalle C, Comijn J, De Craene B, et al: SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 33:6566-6578, 2005. (Pubitemid 41806421)
45. Figueiredo J, Simoes-Correia J, Soderberg O, et al: ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS One 6:e23188, 2011.
46. Pinho SS, Reis CA, Paredes J, et al: The role of N- acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet 18:2599-2608, 2009.
47. Simõ es-Correia J, Figueiredo J, Oliveira C, et al: Endoplasmic reticulum quality control: A new mechanism of E-cadherin regulation and its implication in cancer. Hum Mol Genet 17:3566-3576, 2008.